We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PATH:NYSEUiPath, Inc. Analysis

Data as of 2026-06-21 - not real-time

$10.27

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

UiPath (PATH) trades around $10.27, well below its DCF‑derived fair value of $28.89, implying roughly a 30% upside. The stock’s P/E of 17 is dramatically cheaper than the software‑infrastructure industry average of 38, and it delivers an impressive 83% gross margin with operating margins expanding toward 7% on a revenue base of $1.67 B growing 17% YoY. The balance sheet is strong, featuring over $1.3 B in cash against modest debt of $83 M, and free cash flow exceeds $511 M, supporting the case for a valuation that is currently undervalued.
Technical signals, however, are less encouraging: the price sits below the 20‑day (11.13) and 50‑day (10.69) SMAs, RSI hovers at 42, and MACD shows a bearish divergence, while volatility remains high at over 60% and beta exceeds 1.2. Recent news highlights a solid quarterly performance but also notes a >30% short‑float and a 28% YTD decline, underscoring short‑term pressure despite the “Extreme Greed” market sentiment. Together, the fundamentals suggest upside, yet the technical landscape and elevated risk factors warrant caution in the near term.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • price trading below 20‑day and 50‑day SMAs
  • bearish MACD histogram and neutral RSI
  • high short‑float (>30%) and recent 28% YTD drop

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • DCF fair value indicates ~30% upside
  • robust revenue growth (~17%) and expanding AI automation market
  • improving forward EPS and margin expansion

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • significant valuation gap to fair value
  • strong cash generation and low leverage
  • long‑term tailwinds from AI‑driven process automation

Key Metrics & Analysis

Financial Health

Revenue Growth17.30%
Profit Margin19.58%
P/E Ratio17.1
ROE18.18%
ROA2.37%
Debt/Equity4.36
P/B Ratio2.8
Op. Cash Flow$384.1M
Free Cash Flow$511.6M
Industry P/E38.1

Technical Analysis

TrendNeutral
RSI41.7
Support$9.88
Resistance$13.20
MA 20$11.13
MA 50$10.69
MA 200$13.01
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46

Valuation

Fair Value$28.89
Target Price$13.31
Upside/Downside29.61%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.25
Volatility60.80%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.